Journal
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS
Volume 32, Issue 9, Pages 18-20Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.JAA.0000578788.69674.2b
Keywords
herpes zoster; vaccine; Shingrix; Advisory Committee on Immunization Practices; shingles; varicella
Categories
Ask authors/readers for more resources
The recombinant adjuvanted zoster vaccine (RZV, trade name Shingrix) is preferentially recommended by the Advisory Committee on Immunization Practices to prevent herpes zoster and related complications in immunocompetent adults age 50 years and older. This article reviews efficacy and safety of the vaccine, its use in special populations, and how to prevent administration errors to answer the question Which patients should receive the herpes zoster vaccine?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
